Deterministic cell processing recovers >2-fold more cells, and up to 5-fold more naïve T cells, as compared to centrifugally prepared cells
February 6 – 10, 2022
There are still significant manufacturing challenges impeding the rapid adoption of advanced therapies. The first day of leukapheresis product processing typically requires ~5 steps (~4-6 hours) and incurs significant cell loss prior to cell selection and/or activation steps. Here, we present data from our Curate® cell processing system, a single step process that yields >2 fold more cells with comparable or better quality in under an hour.
Please click Additional Files below to see the full abstract.
Tony Ward, Yasna Behmardi, Laurissa Ouaguia, Cole Jones, Hani Rahmo, Alison Skelley, Khushroo Gandhi, and Roberto Campos-Gonzalez, "Deterministic cell processing recovers >2-fold more cells, and up to 5-fold more naïve T cells, as compared to centrifugally prepared cells" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/7